Results 51 to 60 of about 12,617 (217)
Complement regulator CD46: Genetic variants and disease associations [PDF]
, 2015 Membrane cofactor protein (MCP; CD46) is an ubiquitously expressed complement regulatory protein that protects host cells from injury by complement.
Atkinson, John P, Liszewski, M. Kathryn
core +2 more sources
Modulators of Diacylglycerol Kinase Activity: A Review of Advances and Challenges
Medicinal Research Reviews, Volume 46, Issue 1, Page 149-175, January 2026.ABSTRACT Catalyzing the conversion of diacylglycerol (DAG) in phosphatidic acid (PA), diacylglycerol kinases (DGKs) play a pivotal role in all the physiological processes modulated by these two bioactive lipids, such as lipid metabolism and immune regulation.
Luisa Racca +2 more
wiley +1 more source
BMC Nephrology, 2019 Background Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury.
Subagini Nagarajah +7 more
doaj +1 more source
Romanian Journal of Internal Medicine, 2022 Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of ...
Yeter Hasan H. +5 more
doaj +1 more source
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome [PDF]
, 2007 The atypical form of the kidney disease hemolytic uremic syndrome (aHUS) is associated with defective complement regulation. In addition to mutations in complement regulators, factor H (FH)-specific autoantibodies have been reported for aHUS patients ...
Dahse, H. M. +4 more
core +1 more source
Pathogenesis of Atypical Hemolytic Uremic Syndrome
Journal of Atherosclerosis and Thrombosis, 2019 Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure. aHUS is caused by uncontrolled complement activation in the alternative pathway (AP).
Yoshida, Yoko +3 more
openaire +3 more sources
Veterinary Medicine and Science, Volume 12, Issue 1, January 2026.This study in Western Iran analysed E. coli in diarrhoeic neonatal calves and identified 307 isolates from 350 faecal samples. The pathotypes included EHEC (36.59%), EPEC (20.42%), ETEC (14.46%), STEC (12.34%) and NTEC (11.48%), with four STEC O157:H7 isolates. Serotypes O103 and O15 were the most common.
Elham Ahmadi +3 more
wiley +1 more source
Atypical haemolytic-uraemic syndrome caused by factor H mutation: case report and new management strategies in children [PDF]
, 2012 Atypical haemolytic uraemic syndrome is causedby alternative complement pathway dysregulation. It has recently been recognised that most cases are due to genetic factors and a growing list of mutations has been described.
Araújo, L. +5 more
core
Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]
, 2015 Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael +1 more
core +2 more sources
Probiotic Development Strategy Centered on Stability and Regulatory Considerations
Comprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 1, January 2026.ABSTRACT The development of probiotic strains has become a major focus in both academic and industrial research, driven by their health benefits and growing consumer demand. However, functional outcomes demonstrated under laboratory conditions often fail to align with the stability and large‐scale performance required for industrial applications ...
Hye Kim +5 more
wiley +1 more source